212 related articles for article (PubMed ID: 37295266)
1. Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review.
Nakevska Z; Yokota T
Eur J Cell Biol; 2023 Jun; 102(2):151326. PubMed ID: 37295266
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
Touznik A; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
Son HW; Yokota T
Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
[TBL] [Abstract][Full Text] [Related]
4. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
Farrelly-Rosch A; Lau CL; Patil N; Turner BJ; Shabanpoor F
Neurochem Int; 2017 Sep; 108():213-221. PubMed ID: 28389270
[TBL] [Abstract][Full Text] [Related]
5. Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA.
Leckie J; Yokota T
Molecules; 2024 Jun; 29(11):. PubMed ID: 38893532
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
7. Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation.
Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():455-465. PubMed ID: 30171559
[TBL] [Abstract][Full Text] [Related]
8. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
Hoy SM
CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
[TBL] [Abstract][Full Text] [Related]
9. Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy.
Aslesh T; Yokota T
Cells; 2022 Jan; 11(3):. PubMed ID: 35159227
[TBL] [Abstract][Full Text] [Related]
10. Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of
Toosaranont J; Ruschadaariyachat S; Mujchariyakul W; Arora JK; Charoensawan V; Suktitipat B; Palmer TN; Fletcher S; Wilton SD; Mitrpant C
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409296
[TBL] [Abstract][Full Text] [Related]
11. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy.
Mitrpant C; Porensky P; Zhou H; Price L; Muntoni F; Fletcher S; Wilton SD; Burghes AH
PLoS One; 2013; 8(4):e62114. PubMed ID: 23630626
[TBL] [Abstract][Full Text] [Related]
12. Nusinersen in the Treatment of Spinal Muscular Atrophy.
Goodkey K; Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
[TBL] [Abstract][Full Text] [Related]
13. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype.
Nizzardo M; Simone C; Salani S; Ruepp MD; Rizzo F; Ruggieri M; Zanetta C; Brajkovic S; Moulton HM; Müehlemann O; Bresolin N; Comi GP; Corti S
Clin Ther; 2014 Mar; 36(3):340-56.e5. PubMed ID: 24636820
[TBL] [Abstract][Full Text] [Related]
14. An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy.
Li Y; Zeng H; Wei Y; Ma X; He Z
Hum Gene Ther; 2023 Mar; 34(5-6):180-191. PubMed ID: 36762938
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide.
Haque US; Yokota T
Cells; 2023 Oct; 12(19):. PubMed ID: 37830609
[TBL] [Abstract][Full Text] [Related]
16. Cell-Based Therapy for Spinal Muscular Atrophy.
Han F; Ebrahimi-Barough S; Abolghasemi R; Ai J; Liu Y
Adv Exp Med Biol; 2020; 1266():117-125. PubMed ID: 33105498
[TBL] [Abstract][Full Text] [Related]
17. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
Wood MJA; Talbot K; Bowerman M
Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
[TBL] [Abstract][Full Text] [Related]
18. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model.
Sheng L; Rigo F; Bennett CF; Krainer AR; Hua Y
Nucleic Acids Res; 2020 Apr; 48(6):2853-2865. PubMed ID: 32103257
[TBL] [Abstract][Full Text] [Related]
20. Nusinersen: First Global Approval.
Hoy SM
Drugs; 2017 Mar; 77(4):473-479. PubMed ID: 28229309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]